Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Magenta Therapeutics stock

Learn how to easily invest in Magenta Therapeutics stock.

Magenta Therapeutics Inc is a biotechnology business based in the US. Magenta Therapeutics shares (MGTA) are listed on the NASDAQ and all prices are listed in US Dollars. Magenta Therapeutics employs 70 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Magenta Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGTA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Magenta Therapeutics stock price (NASDAQ: MGTA)

Use our graph to track the performance of MGTA stocks over time.

Magenta Therapeutics shares at a glance

Information last updated 2022-09-26.
Latest market close$1.34
52-week range$0.92 - $8.49
50-day moving average $1.75
200-day moving average $2.47
Wall St. target price$5.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.33

Buy Magenta Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Magenta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Magenta Therapeutics price performance over time

Historical closes compared with the close of $1.34 from 2022-09-27

1 week (2022-09-22) -6.94%
1 month (2022-08-29) -22.09%
3 months (2022-06-29) 15.52%
6 months (2022-03-29) -60.36%
1 year (2021-09-28) -81.72%
2 years (2020-09-29) -80.41%
3 years (2019-09-27) 9.63
5 years (2017-09-25) N/A

Magenta Therapeutics financials

Gross profit TTM $0
Return on assets TTM -25.38%
Return on equity TTM -45.45%
Profit margin 0%
Book value $2.32
Market capitalisation $83 million

TTM: trailing 12 months

Magenta Therapeutics share dividends

We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.

Magenta Therapeutics share price volatility

Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $0.92 up to $8.49. A popular way to gauge a stock's volatility is its "beta".

MGTA.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 2.0763. This would suggest that Magenta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Magenta Therapeutics overview

Magenta Therapeutics, Inc. , a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc.

Frequently asked questions

What percentage of Magenta Therapeutics is owned by insiders or institutions?
Currently 7.974% of Magenta Therapeutics shares are held by insiders and 71.231% by institutions.
How many people work for Magenta Therapeutics?
Latest data suggests 70 work at Magenta Therapeutics.
When does the fiscal year end for Magenta Therapeutics?
Magenta Therapeutics's fiscal year ends in December.
Where is Magenta Therapeutics based?
Magenta Therapeutics's address is: 100 Technology Square, Cambridge, MA, United States, 02139
What is Magenta Therapeutics's ISIN number?
Magenta Therapeutics's international securities identification number is: US55910K1088
What is Magenta Therapeutics's CUSIP number?
Magenta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55910K108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site